CLDN3 and ovarian carcinoma: Because claudin-3 and claudin-4 have been recognized as the receptors for Clostridium perfringens enterotoxin (CPE), these findings imply that ovarian cancer refractory to standard treatment modalities may be susceptible to CPE-based therapeutic approaches.